{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T19:40:17Z","timestamp":1782502817219,"version":"3.54.5"},"reference-count":17,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2009,3,11]],"date-time":"2009-03-11T00:00:00Z","timestamp":1236729600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2009,8]]},"abstract":"<jats:sec><jats:title>Abstract<\/jats:title><jats:p><jats:bold>Background and objective\u2002<\/jats:bold> Treatment in psoriasis vulgaris continues to unmet needs in terms of efficacy, quality of life and costs. Patients with moderate forms of psoriasis are using topical corticosteroids as first\u2010line therapy and patients with severe forms also use this therapy. Optimization of this treatment is made by the use of combination drugs or by the sequential or rotational therapies. A multicentric clinical study was performed to measure the efficiency of mometasone furoate 0.1% and salicylic acid 5% and mometasone furoate 0.1% as sequential local therapy in psoriasis.<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> This was a randomized, multicentre trial with two patient groups receiving active treatment. The study group (<jats:italic>N<\/jats:italic>\u00a0=\u00a0184) received mometasone furoate 0.1% and salicylic acid 5% for the first 7\u00a0days of treatment, and in the following 14\u00a0days, the patients used mometasone furoate 0.1%. The second group (<jats:italic>N<\/jats:italic>\u00a0=\u00a0176) was treated with mometasone furoate 0.1% for 21 consecutive days. Psoriasis Area Severity Index (PASI) score and Dermatology Life Quality Index (DLQI) were calculated.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> After the first week of treatment in the study group, the reduction of PASI score was 44%, statistically significant greater than the reduction of PASI score in the second group (37%). Quality of life estimated by DLQI indicated significant lower values in the first (study) group.<\/jats:p><jats:p><jats:bold>Conclusion\u2002<\/jats:bold> The sequential treatment mometasone furoate 0.1% and salicylic acid 5% followed by mometasone furoate 0.1% proves to be efficient, safe and an excellent option for the following sequence: in\u2010patient and out\u2010patient.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conflict of Interest<\/jats:title><jats:p>None declared.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1468-3083.2009.03214.x","type":"journal-article","created":{"date-parts":[[2009,3,11]],"date-time":"2009-03-11T03:55:36Z","timestamp":1236743736000},"page":"905-912","source":"Crossref","is-referenced-by-count":24,"title":["Mometasone furoate 0.1% and salicylic acid 5% vs. mometasone furoate 0.1% as sequential local therapy in psoriasis vulgaris"],"prefix":"10.1111","volume":"23","author":[{"given":"G\u2010S","family":"Tiplica","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"CM","family":"Salavastru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,7,6]]},"reference":[{"issue":"2","key":"e_1_2_8_2_2","first-page":"ii","article-title":"Psoriasis: epidemiology, clinical features and quality of life","volume":"64","author":"Langley RG","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2005.06502.x"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1159\/000250839"},{"key":"e_1_2_8_5_2","first-page":"183","article-title":"Treatment of psoriasis","volume":"33","author":"Allen BR","year":"1993","journal-title":"Prescr J"},{"key":"e_1_2_8_6_2","first-page":"480","article-title":"Mometasone furoate ointment and cream 0.1 percent in treatment of psoriasis: comparison with ointment and cream formulations of fluocinolone acetonide 0.025 percent and triamcinolone acetonide 0.1 Percent","volume":"42","author":"Medansky RS","year":"1988","journal-title":"Cutis"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.3109\/09546639809160546"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2000.105167"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-199206000-00002"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1994.tb01167.x"},{"key":"e_1_2_8_11_2","unstructured":"http:\/\/www.ms.ro\/legislatiein vigoare (2008)."},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(08)81783-5"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2005.06893.x"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.3109\/08923979109019704"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1976.tb00825.x"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1980.tb06590.x"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(98)80091-X"},{"key":"e_1_2_8_18_2","first-page":"32","article-title":"Topical corticosteroids","volume":"21","author":"Greaves MW","year":"1987","journal-title":"J Roy Coll Phys"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-3083.2009.03214.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-3083.2009.03214.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T22:00:07Z","timestamp":1697061607000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-3083.2009.03214.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7,6]]},"references-count":17,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["10.1111\/j.1468-3083.2009.03214.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-3083.2009.03214.x","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,7,6]]}}}